QR Code

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF). Post hoc analyses herein evaluated the efficacy and safety of momelotinib in patients with MF and thrombocyto...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Miklos Egyed, Uwe Platzbecker, Jiří Mayer, Sebastian Grosicki, Árpád Illés, Tomasz Woźny, Stephen T. Oh, Donal McLornan, Ilya Kirgner, Sung-Soo Yoon, Claire N. Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben Mesa
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Wiley 2023-11-01
Rangatū:HemaSphere
Urunga tuihono:http://journals.lww.com/10.1097/HS9.0000000000000963
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite